Drugs / IPX203
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT03007888 | Nov 2016 → Aug 2017 | Parkinson disease | Impax Laboratories, LLC | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03877510 | Apr 2019 → Mar 2022 | Parkinson disease | Impax Laboratories, LLC | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IPX203 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03007888 ↗ |
| Route | Oral | “oral administration” NCT03877510 ↗ |